c-Myc, a proto-oncogene that is implicated in tumorigenesis, embryonic development and apoptosis, can physically associate with BRCA1. We have found that BRCA1 interacts with c-Myc in yeast, in in vitro assays and in mammalian cells. Endogenous interactions between BRCA1 and c-Myc were also observed. Ecient BRCA1-Myc association requires the intact helix ± loop ± helix region of c-Myc, a motif involved in Myc ± Max dimerization. BRCA1 does not however bind to Max. Our studies revealed that BRCA1 represses Mycmediated transcription while having no eect on some other transcriptional activities. Furthermore, BRCA1 reverses the phenotype of embryonic ®broblasts transformed by the activation of Myc and Ras, but only minimally aects the transformed phenotype induced by SV40 virus. These data indicate that BRCA1 may function as a tumor suppressor by regulating the behavior of c-Myc and provide a molecular explanation for some of the eects of the BRCA1 gene product.
Introduction
The breast cancer susceptibility gene BRCA1 is mutated in approximately 20 ± 45% of inherited breast cancers (Couch et al., 1997; Easton et al., 1995; Struewing et al., 1997) . Detection of loss of heterozygosity (LOH) in tumors would suggest that it is a tumor suppressor (Neuhausen and Marshall, 1994) . In fact, BRCA1 causes growth retardation when stably transfected into breast or ovarian cell lines (Holt et al., 1996) , and the reduction of BRCA1 protein levels seen after introduction of antisense nucleotides seems to enhance cell proliferation Thompson et al., 1995) . Phosphorylation levels of BRCA1 appear to change in a cell-cycle dependent manner (Chen et al., 1996b; Runer and Verma, 1997; Zhang et al., 1997) . Collectively, these observations suggests that BRCA1 may be involved in some aspects of cell cycle progression.
The human BRCA1 cDNA encodes a protein of 1863 amino acid residues (Miki et al., 1994) . BRCA1 contains at least two nuclear localization sequences (NLS), which are required for translocation into the nucleus (Chen et al., 1996a) . The N-terminal region of BRCA1 includes a RING domain, a motif conserved in many other nuclear proteins (Borden and Freemont, 1996) . This region has been shown to interact with BARD1, itself a RINGdomain protein (Wu et al., 1996a) . The C-terminal region of BRCA1 is rich in acidic amino residues and can act as a transcription factor when it is fused with the Gal4 DNA binding domain (Chapman and Verma, 1996; Monteiro et al., 1996) . In addition, a putative globular domain in the C-terminus (BRCT) has some homology with Rad9, a yeast protein involved in mediating a cell cycle checkpoint for DNA damage and with 53BP1, a p53 binding protein (Callebaut and Mornon, 1997; Koonin et al., 1996) .
Recently, several lines of evidence have indicated that BRCA1 may mediate multiple functions in the cell, including a role in DNA damage repair and in gene transcription. Scully et al. (1997c) found that BRCA1 interacts and co-localizes with Rad51, a human homologue of bacterial recA protein. BRCA1, Rad 51, and BARD1 co-exist in the nuclear dot-like structures (nuclear foci) at S phase, as shown by immuno¯uorescence. In addition, BRCA1 seems to be re-located within the cell and become hyperphosphorylated in response to DNA damage (Scully et al., 1997b) . However, it is not known whether BRCA1 is directly involved in DNA damage repair, or if it mediates a checkpoint that responds to DNA damage repair.
The presence of a transactivation domain suggests that BRCA1 might be involved in gene transcription. Consistent with this notion, BRCA1 can associate with the RNA polymerase II holoenzyme (Scully et al., 1997a) . In contrast, a mutation in the C-terminus of BRCA1 reduces the eectiveness of the association with the polymerase (Scully et al., 1997a) .
In this study, we have isolated c-Myc as a BRCA1-binding protein using the yeast two-hybrid system. We demonstrate that BRCA1 interacts with c-Myc and aects cellular phenotypes caused by the synergistic actions of c-Myc and Ras, but is far less able to inhibit the phenotype of SV40 transformed rodent ®broblasts. These ®ndings are consistent with the notion that BRCA1 is a component of a transcription factor complex and may function as a tumor suppressor, at least in part, by regulating the activity of the c-Myc proto-oncogene.
Results

BRCA1-Myc interaction in yeast
We used the yeast two-hybrid screening method to search for proteins that interact with BRCA1. A central region of BRCA1 (303 ± 1142) was subcloned in-frame with the Gal4 DNA binding domain to generate the bait construct pGalBD-BRRN (Figure 1) . The Gal4-BRCA1 fusion protein demonstrates minimal transactivation activity, which activates the HIS3 reporter independent of a prey construct. However, this`background' level of HIS3 expression can be suppressed by 3-amino-triazol (3AT) when used at a concentration of 5 mM. We screened a HeLa cell library and isolated a clone that carries an in-frame fusion of the carboxyl-terminal region of c-Myc (251 ± 439) to the Gal4 transactivation domain, designated pGAD-MycT. Co-transformation of pGalBD-BRRN and pGAD-MycT activates the HIS3 reporters, while neither plasmid alone is able to do so (Table 1) . This suggests that BRCA1 physically interacts with c-Myc in the two-hybrid system. In our studies, the Cterminal portion of p53 (72 ± 390) fails to interact with c-Myc, and BRCA1 does not bind to Max. Interestingly, and unexpectedly, the amino-terminal region of BRCA1 (1 ± 303) also interacts with c-Myc by the same criteria (Table 1) . Therefore, we conclude, BRCA1 contains two regions that independently interact with c-Myc in yeast.
Localization of the Myc-binding regions of BRCA1
We next generated a series of Gal4BD-BRCA1 deletion mutants to map the regions required for interaction with c-Myc. As shown in Figure 1 , a small segment of BRCA1 (amino acid residue 433 ± 511, as in pGalBD-BRMS) is both required and sucient for binding to cMyc. We designated this region MB1 (for Myc-binding region 1). An N-terminal Myc-binding region (termed MB2) of BRCA1 requires amino acid residues 175 ± 303. The two regions span exons 8, 9, 10 and the Nterminal portion of exon 11. It was of interest to note that the intervening segment between the two Mycbinding regions, amino acid residues 343 ± 433, appears to account for the basal transcription activity of the Gal4-BRCA1 (303 ± 1142) fusion protein ( Figure 1 ). This intervening region is not required for binding to Myc and when it was deleted, we were able to observe BRCA1-Myc interaction without using any 3AT in the medium (Figure 1 , constructs BRMS(433 ± 511) and BRMP(433 ± 927)). A close examination of the sequence revealed that this region is rich in acidic amino acids (27 out of 101 amino residues), a feature shared by many transcription factors. However, the transactivation activity of this region is much lower than that of the C-terminal domain (data not shown).
BRCA1-Myc interaction in vitro
An in vitro binding assay was employed to con®rm BRCA1-Myc interactions. GST fusion proteins, GSTMyc (251 ± 439, called GST-MycT), GST-Myc (1 ± 261), GST-Max, GST-BARD1, or GST itself, were synthesized in bacteria. BARD1 is known to interact with BRCA1 through the N-terminal region and served as a positive control. The full length or deletion mutants of BRCA1 protein were generated by in vitro translation (IVT) and labeled with 35 S-cysteine. A series of BRCA1 deletion mutants were used ( Figure 2A ). BR(D175 ± 625) has a deletion of both Myc-binding regions. The glutathione sepharose beads loaded with similar amounts of GST or GST-fusion proteins were mixed and incubated with the in vitro translation products. After precipitation and extensive washing, the proteins bound to the beads were subjected to SDS ± PAGE. As demonstrated in Figure 2B , BRCA1 was pulled down by GST-MycT or GST-BARD1, but not by GST-Myc(1 ± 261), GST-Max or GST alone. Deletion of MB1 and MB2, as in the BR(D178 ± 625), or in BR(773 ± 1863) form, reduced the association to background levels.
Localization of the BRCA1-binding region of c-Myc
The C-terminal region of c-Myc contains a basic region that is involved in DNA-binding, a helix ± loop ± helix Figure 1 Localization of Myc-binding region on BRCA1. A series of Gal4BD-BRCA1 fusion constructs were transformed either with pGAD-MycT, or with the empty vector pGAD424. The double-transformants were then streaked out onto -L-T-H SD plates containing the indicated amount of 3AT (in mM). The growth of the colonies was observed 4 days later. The Gal4-BRCA1 constructs that were able to activate the HIS3 reporter in a Myc-dependent way are designated`+'; those failed to activate are designated`7'.`HB' refers to high background, where the corresponding pGalBD-BRCA1 constructs are able to activate HIS3 reporter when co-transformed with the empty pGAD424 (independent of Myc).`ND' refers to`not determined'. For each construct to be tested, ®ve independent colonies were picked and streaked out (Figure 3a) suggesting that BRCA1 associates with Myc at this region and might aect the formation of Myc-Max heterodimers. We also performed the in vitro binding assay using GST-BRCA1(1 ± 625) and a series of Myc deletion mutants. The HLH region but not the LZ region is required for BRCA1-myc interaction (Figure 3b ). It is noteworthy that both the MB-1 and MB-2 regions of BRCA1 require the same general HLH site on Myc but cannot interact with Max, which possesses similar HLH characteristics.
BRCA1-Myc interaction in mammalian cells
In order to con®rm the BRCA1/Myc interaction in mammalian cells, we co-transfected human embryonic kidney cells (293T) with BRCA1 and hemagglutinin (HA)-epitope-tagged Myc. Two deletion mutants of Myc, HA-MycD(371 ± 412) and HA-MycD(414 ± 439), were also used to de®ne the BRCA1-binding region in the HLH-LZ domain of c-Myc. Forty-eight hours after transfection, cell lysates were prepared and subjected to immunoprecipitation with HA.11, an anti-HA monoclonal antibody. The precipitated complex was then resolved on SDS ± PAGE, followed by Western blotting with C20, an anti-BRCA1 antibody. The C-20 antibody (Wilson et al., 1996) was used on nuclear lysates. Under these circumstances no extra bands that might Scysteine. The glutathione sepharose beads that were loaded with similar amount of GST proteins (5 ± 10 mg) were mixed with 5 ml of in vitro translation products, followed by precipitation, washing and SDS ± PAGE. BRCA1 was precipitated by GST-MycT, or GST-BARD1, but not by GST-Max or GST alone. The 100 kD proteins (in BRCA1 and BR(1 ± 773) IVT) are probably premature in vitro translation products. Deletion of both MB1 and MB2, as in BRD(175 ± 625) or in BR(773 ± 1863), reduced the association to background level. 0.5 ml of the IVT product was loaded on the gel to show the size of the input protein a b Figure 3 Localization of BRCA1-binding region on c-Myc. (a) A series of pGAD-Myc deletion mutants were transformed either with pGBT-BRRP(304 ± 927), or with the parental empty vector pGBT9. The two-hybrid interaction assay was carried out as described in Figure 2 legend and in Materials and methods. Deletion of the HLH-LZ region of Myc, as in pGAD-MycTrx, abolished its binding to BRCA1. (b) Glutathione beads coupled with 5 ± 10 mg of GST-BR(1 ± 625), GST-Max, or GST proteins were incubated with 5 ml in vitro-translated c-Myc or Myc deletion mutant proteins. Proteins bound to the beads were separated by SDS ± PAGE. Deletion of the HLH of MycD(367 ± 412) abolished its binding to both BRCA1 and to Max, while deletion of the LZ region of MycD(414 ± 433) only aected its binding to Max. 0.5 ml of the IVT product was loaded on the gel to show the size of the input protein represent EGFR or ErbB2 have been noted in our studies. Furthermore, we have stripped the membrane and routinely re-probed it with another anti-BRCA1 antibody N-20, and in all cases we have seen only one BRCA1 band at about 215 kD. We also used FLAGtagged full length BRCA1 (FLAG-BRCA1) or Cterminal deletion mutant missing the epitope region (FLAG-BRCA1(DC)) to demonstrate the speci®city of C-20 against BRCA1. After immunoprecipitation by FLAG-tag antibody, the BRCA1 band was only observed in 293T cells transfected by FLAG-tagged full length BRCA1, but not in cells expressing FLAG-BRCA1(DC) (Figure 4a , lanes 1 and 2).
As shown in Figure 4a , BRCA1 was co-precipitated with the full-length HA-Myc (lane 3). BRCA1 was also co-precipitated with the deletion mutant HAMycD(414 ± 439) (lane 5), but failed to be precipitated with HA-MycD(371 ± 412) ( Figure 4a , lane 4), indicating that the N-terminal region of the HLH-LZ domain is critical for BRCA1-binding. For a negative control, we also co-transfected 293T cells with BRCA1 and a non-related HA-tagged protein HA-GCN5. BRCA1 was not co-precipitated with HA-CGN5 by the anti-HA antibody HA.11 (Figure 4a , lane 6), indicating that Myc was required and that the HA.11 antibody did not cross-react with BRCA1. Reciprocally, c-Myc was also co-immunoprecipitated with anti-BRCA1 antibody (Figure 4b ).
Importantly we next showed that nuclear isolates contain the endogenous p62 c-myc (Evan and Hancock, 1985) which associates with endogenous BRCA1 and can be co-immunoprecipitated from 293T cells by two dierent polyclonal BRCA1 antibodies (Figure 4c ). Moreover if fresh 10% Fetal Calf Serum containing medium is not added to plated 293T cells, we cannot detect c-Myc in association with BRCA1 in immunoprecipitates (see Figure 4c ). The reciprocal co-immunoprecipitation was also conducted with two dierent antiMyc antibodies (Figure 4d ). It is noteworthy that some commercially available anti Myc antibodies are not able to precipitate c-Myc in association with BRCA1 (data not shown). Although distinct c-Myc species p62 and p67 are occasionally seen in some cell lines with certain polyclonal antibodies (Hann and Eisenman, 1984; Hann et al., 1988) we have observed primarily the smaller p62 c-myc species in our studies, similar to which has been seen by others (Evan and Hancock, 1985) . Collectively these data suggest that BRCA1 and p62 c-myc form an endogenous protein complex in vivo, and the complex is dependent on certain physiological conditions that may relate to cell growth status.
BRCA1 represses Myc-mediated transcription
c-Myc is a weak transcription factor that binds to the CACGTG motif. Potential c-Myc target genes include ornithine decarboxylase (ODC) and CDC25A (Bello- After 48 h of transfection, cell lysate was collected and subjected to immunoprecipitation with an anti-FLAG monoclonal antibody (FLAGM5, lanes 1 and 2), or an anti-HA monoclonal antibody (HA.11, lanes 3 ± 6). The immuno-complex was then separated by SDS ± PAGE and detected by Western blot using an anti-BRCA1 antibody (C-20). BRCA1 was co-precipitated with HA-Myc by the anti-HA antibody. (b) 293T cells were transfected with HA-Myc in combination with pCR-BRCA1 or the empty vector. Cell lysates were immunoprecipitated with an anti-BRCA1 antibody (H11D), followed by SDS ± PAGE, and immunoblotted with anti-HA antibody (12CA5). c-Myc was co-precipitated with BRCA1. (c) 293T cells were used to study the endogenous interaction between BRCA1 and Myc. Con¯uent cells were split 1 : 3 and kept in 10% FBS containing medium. Twenty hours later, cells were changed to fresh media for 2 h as indicated. Nuclear lysates (lane 1) were prepared as described previously (9). One mg of nuclear lysate was used for immunoprecipitation for each lane. Polyclonal anti BRCA1 antibodies, Ab-1 (Neomarkers) and C-20 (Santa Cruz Laboratories), were used to immunoprecipitate the lysates. The complexes were run on a 10% SDS ± PAGE gel and transferred to nitrocellulose for Western blotting with the 9E10 monoclonal anti Myc antibody (Neomarkers). A polyclonal anti-Myc antibody (kindly provided by Dr Virginia Lee) was used for immunoprecipitation followed by Western blotting with 9E10. The Myc band is indicated by arrows. (d) 293T nuclear lysates were prepared as in (c). Monoclonal anti Myc antibodies, Ab-4 (Neomarkers) and 9E11 (Neomarkers) were used to immunoprecipitate the lysates. The complexes were run on a 6% SDS ± PAGE gel and transferred to nitrocellulose for Western blotting with the C-20 polyclonal anti-BRCA1 antibody (Santa Cruz Laboratories) Fernandez et al., 1993; Galaktionov et al., 1996; Pena et al., 1993) . CDC25A plays a role in cell cycle transition from the G 1 to S phase by activating cyclindependent kinases. Even though an essential role for Myc in its regulation of ODC and CDC25A in vivo in cycling cells has not been established, we asked operationally whether BRCA1 would aect Mycmediated transcription and used two Myc-activated reporter constructs for these studies. PM4minluc is a luciferase reporter driven by four CACGTG repeats and the E1b minimal promoter (Figure 5a ). P0.7WTNP-luc is a luciferase reporter under the control of CDC25A natural promoter and a Mycbinding site from intron 2 of CDC25A (Galaktionov et al., 1996) .
As shown in Figure 5a , c-Myc activates the reporter pM4min-luc 3 ± 4-fold. Co-transfection of BRCA1 abolished the activation in a dose-dependent manner. In contrast, the MB deletion mutants, BR(773 ± 1864), has little eect. In addition, USF-VP16 also activates the reporter pM4min-luc fourfold; yet it cannot be inhibited by BRCA1 (Figure 5b ). BRCA1 also aected Myc activity similarly on the CDC25A promoter (Figure 5c ). In these reporter gene experiments, a plasmid containing b-galactosidase controlled by the CMV promoter (pCMVb) was used as a normalizing control, and we did not observe any correlation between b-galactosidase activity and BRCA1 expression (not shown), suggesting that BRCA1 cannot aect the CMV promoter. Moreover, BRCA1 does not inhibit the expression of the reporters driven by either the E1b minimal promoter (pmin-luc) or the CDC25A natural promoter with mutated Myc-binding sites (pMutNP-luc) (Figure 5d and e) . Collectively, these observations ruled out the possibilities that BRCA1 acts as a general transcription inhibitor or that it aects transcription due to a detrimental eect on cells. Therefore, our results suggest that BRCA1 negatively and speci®cally regulates Myc-mediated transcription.
Suppression of Myc-Ras co-transformation by BRCA1
We investigated the eects of BRCA1 on Mycmediated transformation. Under certain conditions, cMyc can transform embryonic cells in cooperation with mutant H-ras, while c-Myc or H-ras alone is not sucient to induce transformation in the rat embryonic ®broblasts (REF) (Land et al., 1983 (Land et al., , 1986 . Since BRCA1 performed as a negative regulator in the Mycmediated transcription experiments, we predicted that it might act in a similar way to suppress Myc-mediated transformation. To avoid artifacts due to using single cloned cell lines, we used a Myc-Ras-transfected REF cell pool to address this issue. The BRCA1 cDNA was cloned into the bicistronic expression vector pIRES1hyg. pCMVb was included as an internal control for transfection eciency. An aliquot of transfected cells was used for in situ X-gal staining to ascertain that transfection eciency was comparable (10 ± 13%). Only cells that were transfected survived in the presence of selection. As shown in Table 2 and Figure 6 , transformed foci still readily formed in control cells transfected with the pIRES1hyg vector. However, transfection of BRCA1 signi®cantly reduced the number of transformed foci, resulting in about 90% less foci compared with the vector transfected cell.
To test if the inhibition of BRCA1 on foci formation is speci®c to Ras/c-Myc mediated transformation, we used the SV40-transformed mouse embryo ®broblast cell line SVD-P5 described by Benjamin (Greene et al., 1982) as a control in a similar set of experiments. We did not observe any reduction in the numbers of foci formed in BRCA1-expressing SVD-P5 cells (Table 2 ). These observations support the idea that a critical mechanism of BRCA1 action is to limit the activity of the c-Myc protein, although we do not exclude the possibility that BRCA1 may have eects on other transforming oncogenes.
Discussion
BRCA1-Myc interaction
c-Myc is a proto-oncogene that promotes cell proliferation (Henriksson and Luscher, 1996; Lemaitre et al., 1996) , while overexpression of c-Myc can also induce apoptosis when coupled with serum deprivation . c-Myc also mediates a critical role in embryonic development, and mouse embryos de®cient in c-Myc die between 9.5 ± 10.5 days of gestation (Davis et al., 1993) . c-Myc has the characteristics of a transcription factor and contains a transactivation domain (TAD), a DNA-binding basic region, and a helix ± loop ± helix ± leucine zipper (HLH-LZ) domain which is involved in dimerization with its partner, Max . Both the TAD and basic-HLH-LZ regions are required for cellular transformation and apoptosis .
Formation of Myc-Max heterodimers is thought to be required for Myc function as the heterodimers bind to speci®c DNA sequences (CACGTG) (Amati et al., 1992 Prendergast and Zi, 1992) . We have shown that BRCA1 also binds to the HLH region of c-Myc. Therefore, it is possible that BRCA1 down-regulates Myc activity by preventing either the formation of a Myc ± Max heterodimer or the binding of Myc ± Max complex to DNA. It is also possible that BRCA1 represses transcription through the action of a BRCA1-Myc-Max complex. However, we did not detect direct interactions between BRCA1 and Max in our studies.
It is noteworthy that the interaction between some polypeptides, such as CREB-binding protein (CBP) and HNF4 transcription factor, BRCA2 and Rad51, or pRb and c-Jun (Sharan et al., 1997; Yoshida et al., (Xu et al., 1997) . These ®ndings raise the possibility that Myc-BRCA1 association may potentially be regulated by dierential spliced forms of BRCA1. The Myc-BRCA1 interaction may also be aected by the BRCA1 phosphorylation state. A variety of ®ndings from dierent investigators has established that the phosphorylation levels of BRCA1 change with respect to the cell cycle (Chen et al., 1996b; Runer and Verma, 1997; Wang et al., 1997; Zhang et al., 1997) . At least three other transcription factors, YY1 (Yin Yan), AP-2 and TFII-I, are known to interact with cMyc in the c-terminal region (Gaubatz et al., 1995; Shrivastava et al., 1993 Shrivastava et al., , 1996 . YY1 binds to the promoters that contain the initiation element (Inr) and either activates or represses transcription according to the promoter context (Henriksson and Luscher, 1996; Lemaitre et al., 1996; Riggs et al., 1993; Shi et al., 1991) . YY1 can compete with Max for binding to cMyc (Shrivastava et al., 1993) . AP-2 binds to DNA and has been shown to modulate transcription of a variety of genes, including p21WAF1/CIP1 (Zeng et al., 1997) . Binding of AP-2 to c-Myc is also able to inhibit Myc-mediated transcription (Gaubatz et al., 1995) and AP-2 is a described negative regulator of cell proliferation. Finally, c-Myc appears to associate with TFII-I, a transcription initiation factor, leading to inhibition of transcription initiation at promoters containing the initiator elements (Roy et al., 1993) . It is therefore possible that BRCA1 competes with YY1, AP-2 or TFII-I for binding to c-Myc and aects transcription from a variety of relevant promoter sites. Meanwhile, each of these Myc-binding proteins may be linked to dierent pathways that lead to downmodulation of c-Myc activity.
Myc functions may also be inhibited via other mechanisms. For example, Max ± Max homodimers, which lack transactivation domains, compete with Myc ± Max heterodimers for binding to the CACGTG motif (Wu et al., 1996b) . Max heterodimerizes with Mad or Mxi and can repress Myc-mediated transcription (Kretzner et al., 1992) . Other proteins, including p107 and AP-2, also bind to c-Myc and inhibit its transcription activity. Our ®nding that BRCA1 repressed Myc-mediated transcription adds yet another level of regulation to the Myc network.
BRCA1, c-Myc and tumorigenesis
c-Myc is one of the early-response genes that are activated transcriptionally in the G 1 phase of the cell cycle. Notably the expression of c-Myc is apparent throughout the cell cycle. Increasing the level of c-Myc proteins may speci®cally aect (shorten) the duration of the G 1 phase of the cell cycle (Karn et al., 1989) . cMyc activates the expression of a series of genes, some of which may be relevant to cycling cells, including ODC (Bello-Fernandez et al., 1993; Pena et al., 1993) , CDC25A (Galaktionov et al., 1996) , a-prothymosin (Eilers et al., 1991) , and the translation initiation factors eIF-2a and eIF-4E (Henriksson and Luscher, 1996; Lemaitre et al., 1996) .
Constitutively high levels of c-Myc expression in cells results in reduced growth factor requirements and increased growth rates that may circumvent cell cycle arrest in some cases. Microinjection of full length cMyc protein abrogates the G 1 phase arrest of cycling Saos cells, induced by the retinoblastoma protein (Goodrich and Lee, 1992) , suggesting that Myc antagonizes some of the suppressor functions of Rb. On the other hand, reduced c-Myc expression leads to a slower growth rate and delayed entry into the S phase (Roussel et al., 1991) of the cell cycle. c-Myc antisense oligonucleotide that inhibits c-Myc expression can block entry to S phase in T and myeloid cells (Heikkila et al., 1987; Prochownik et al., 1988) . In addition, rat ®broblasts defective of c-Myc proliferate signi®cantly more slowly, suggesting that c-Myc is required for cell cycle progression (Mateyak et al., 1997) . c-Myc activation appears to be promoted or aected by the activity of Src tyrosine kinases via a pathway distinct from the Ras/Raf pathway that activates AP1 (Barone and Courtneidge, 1995) and our studies suggest that BRCA1 may therefore act as an indirect regulator of the src signaling pathway.
We showed that BRCA1 represses Myc-mediated transcription through studies employing both the synthetic and CDC25A promoters as operational examples of inhibition of known Myc targets. This observation suggests that one mechanism by which BRCA1 acts as a tumor suppressor is the downmodulation of some (perhaps yet unde®ned) targets of c-Myc transcriptional activity. Loss of BRCA1 function may result in relatively increased Myc activity and therefore a higher susceptibility to cellular transformation. However, mice heterozygous for BRCA1 defective gene develop normally and remain tumor-free for at least 12 months. Nevertheless, it is possible that tumors may develop in these animals at a later stage of life. Moreover, Myc-mediated transformation may require the cooperation of a second transforming gene, which may predispose to a longer latency in tumorigenesis (Sinn et al., 1987) . In vivo mammary adenocarcinomas developed with substantial latency in transgenic mice expressing c-Myc under the control of the mouse mammary tumor virus (MMTV) long terminal repeat (LTR). Double transgenic mice carrying MMTV-Myc and activated Ha-ras showed a dramatic acceleration in tumor development. Although the synergistic interaction of Myc and Ras are not currently understood in molecular terms (Leone et al., 1997) , it is thought that a Myc box 2-dependent event, perhaps through gene repression, is needed for cooperativity (MacGregor et al., 1996) . Finally, it is apparent that c-Myc is able to repress the expression of certain genes, such as the ones containing indicator (Inr) elements (MacGregor et al., 1996; Roy et al., 1993) . We are currently determining whether BRCA1 can antagonize the activity of c-Myc on promoters that are repressed by c-Myc.
Some other factors aect Myc expression and functions. Estrogens and progesterone have been shown to increase c-Myc expression in a number of tissues in vivo over time (Hou et al., 1996; Kirkland et al., 1992) . Also, EGF can promote some features of the transformed phenotype in Myc expressing mesenchymal ®broblasts (Moshier et al., 1995; Stern et al., 1986; Zhang et al., 1997) . Myc transgenes targeted to the breast cooperate with TGFa (ErbB ligand) transgenes to cause mammary gland tumors in young virgin female mice (Sandgren et al., 1995) , supporting a general role for these types of ligands in aecting Myc mediated transformation.
BRCA1, c-Myc and genomic stability
Surprisingly, BRCA1 null mice display general retarded cell proliferation (Hakem et al., 1996) . One possible explanation is that loss of BRCA1 causes or permits damage to DNA and the damaged DNA invokes a cell cycle arrest or checkpoint. This is supported by the observation of BRCA1-RAD51 association (Scully et al., 1997c) . Moreover, BRCA1 becomes hyperphosphorylated in response to irradiation, coupled with its disappearance from the apparent BRCA1/Rad51 dot-like structure (Scully et al., 1997b) . Genomic instability has also been observed in p53 de®cient animals which display elevated c-Myc levels (Fukasawa et al., 1997) . In this regard, wild type p53 can reduce transcription from the c-Myc promoter in vitro (Ragimov et al., 1993) by interference with assembly of the transcription preinitiation complex. Finally, c-Myc overexpression precedes c-Myc gene ampli®cation (Mai et al., 1995) , suggesting that elevated Myc protein levels play a role in amplification of chromosomal events.
Overexpression of c-Myc promotes apoptosis that was initially thought to be a p53-dependent phenomenon (when accompanied by serum deprivation) . However signi®cant evidence of in vivo apoptosis in many tissues is seen in p53 null mice that overexpress c-Myc (Fukasawa et al., 1997) . Mycinduced apoptosis requires complete transcriptional activity of the c-Myc polypeptide, since mutations that abolish Myc transcription activity abrogated the induction of programmed cell death. Our work suggests that BRCA1, by association with c-Myc, may also have dual functions as a mediator for both proliferation and apoptosis. The fact that BRCA1 inhibits Myc-mediated transcription suggests that it may block Myc-induced apoptosis. Intriguingly, cells undergo apoptosis with low serum when stably transfected with a deletion mutant of BRCA1 that lacks most of the exon 11 . It is possible that BRCA1 plays a role in transducing a signal from DNA damage to the switch of cell cycle arrest versus apoptosis. While considering these in vitro possibilities, we are aware that signi®cant apoptosis has not to date been detected in BRCA1 null mice (Hakem et al., 1996) , and a role of BRCA1 in developmentally relevant apoptosis therefore remains to be established.
The emerging role of BRCA1 in regulating transcription, DNA damage repair and perhaps other functions indicates that many molecular species can form assemblies with it. The stoichiometry and disposition of the various BRCA1 ensembles within a cell may determine its role in tumorigenesis and development.
Materials and methods
Cells, plasmids and antibodies
NIH3T3, Cos-7, or 293T cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS). pCR3-BRCA1 was supplied by Dr Barbara Weber (University of Pennsylvania, USA). The FLAG-tagged BRCA1 was constructed in pCDNA3.1(+) (Invitrogen). The Myc-binding region deletion mutant BRD(175 ± 625) was made in pBSK-BRCA1 by removing a AatII ± SpeI fragment, modifying the ends with T4 DNA polymerase and subsequent religation. The resultant deletion mutant was then subcloned into pCDNA3.1(+). All mutants were con®rmed by sequencing. The c-Myc plasmids pSp-Myc and pSV-Myc were gifts from Dr Robert Eisenman (University of Washington, USA) and Dr K Soprano (Temple University), respectively. Myc C-terminal deletion mutants were gifts from Dr William Lee (University of Pennsylvania, USA) and subcloned into pFLAG-Myc or pHA-Myc to create MycD(265 ± 367), MycD(371 ± 412) and MycD(414 ± 433). BARD1 was isolatd in a two-hybrid screening using BRCA1 (1 ± 303) as a bait. All GST fusion constructs were formulated in the pGEX5X vector series (Pharmacia). All HA-tagged constructs were made in pCDNA3.1. For transfection in the focus formation experiments, BRCA1 cDNA were cut out from pCR3-BRCA1 by HindIII and NotI, blunted by T4 DNA polymerase, and then ligated into bicistronic expression vector pIRES1hyg (Clontech, Inc.). The BRCA1 antibody C-20 was purchased from Santa Cruz Biotechnology. The monoclonal HA-tag antibody HA.11 was purchased from BabCo.
Yeast two-hybrid assay
The Clontech Gal4 Matchmaker two-hybrid system was used. The screening procedure was performed according to the user's manual. Brie¯y, the bait construct pGBT9-BRRN was made by subcloning the EcoRI ± NsiI fragment of BRCA1 to pGBT9. A HeLa cell library was screened in yeast strain HF7c. 3AT was used at a concentration of 5 mM. The isolated clone that carries the C-terminal portion of c-Myc was designated pGAD-MycT.
In vitro GST pull-down assay GST constructs were made in the pGEX-5X series of plasmids (Pharmacia), expressed in bacterial and isolated with glutathione sepharose beads according to the instruction of the manufacturer. Expression of the proteins was con®rmed by SDS ± PAGE. BRCA1 or the deletion mutants were expressed and radioactively labeled using the TNT in vitro translation (IVT) system (Promega). Glutathione sepharose beads loaded with about 5 ± 10 mg of GST or GST fusion proteins were incubated with 5 ml of IVT products in 300 ml of binding buer (50 mM HEPES, pH=7.5, 200 mM MaCl, 0.5% NP-40, 1% BSA, 1 mM DTT). After two hours of incubation at room temperature, the beads were precipitated and washed four times with the binding buer. Proteins bound to the beads were separated by SDS ± PAGE and followed by autoradiography. 0.5 ml of the IVT product was loaded on the gel to show the size of the input protein.
Co-immunoprecipitation and Western blot
293T cells were transfected with the corresponding BRCA1 and c-Myc constructs, as speci®ed in the ®gure legends. Forty-eight hours after transfection, cells were lysed in lysis buer (150 mM NaCl, 20 mM Tris HCl (pH 8.0), 0.2 mM EDTA, 1 mM PMSF, 10% Glycerol, 1% Triton X-100) and the supernatant was subjected to immunoprecipitation with the antibody as indicated in each experiment. SDS ± PAGE and Western blots were carried out subsequently.
Luciferase assay
Cells were transfected with lipofectamine and the amount of DNA as indicatd in the ®gures (including 250 ng of reporter, 250 ng of pCMVb). Cells were collected 36 h after transfection and analysed for luciferase activity using a luciferase assay system (Promega). Luciferase activity was corrected for transfection eciency using the bgalactosidase activity. Error bars are based on standard deviation.
Focus formation assay
Myc/Ras-transformed REF cells or SVD-P5 cells (10 5 cells per well) were co-transfected with normalizing plasmid pCMVb (0.5 mg) and expressing plasmid pIRES1-BRCA1-hyg or pIRES1hyg (1 mg). Forty-eight hours after transfection, 10 5 REF cells, or 3610 3 SVD-P5 cells, were plated into a 60-mm dish in DMEM medium with 5% FBS and 200 mg/ml of hygromycin B. Media were changed every 3 days. Twelve days after transfection, transformed foci were scored after cells were ®xed with 10% formalin and stained with hematoxylin. An aliquot of transfected cells was also saved for in situ X-gal staining to ascertain that transfection eciency was comparable (10 ± 13%). All experiments were performed in triplicate and three independent transfections were performed.
